Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 617-621

  Cheng, Steven ^a   Coyne, Daniel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Active vitamin D; Hypercalcaemia; Hyperphosphataemia; Paricalcitol

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DRUG CAPSULE; DRUG FORMULATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPHOSPHATEMIA; NAUSEA AND VOMITING; NONHUMAN; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

CAPSULES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS; VITAMIN D; VITAMINS;

EID: 33645811904     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.617     Document Type: Article

References (40)

1. GALLIENI M, BRANCACCIO D, PADOVESE P et al.: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int. (1992) 42:1191-1198.
2. DRESSLER R, LAUT J, LYNN RI, GINSBERG N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin. Nephrol. (1995) 43:324-331.
3. SLATOPOLSKY E, BERKOBEN M, KELBER J et al.: Effects of calcitriol and non-calcemia vitamin D analogs on secondary hyperparathyroidism. Kidney Int. Suppl. (1992)38:S43.
4. MALBERTI F, CORRADI B, COSCI P, CALLIADA F, MARCELLI D, IMBASCIATI E: Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparthyroidism. Am. J. Kidney Dis. (1996) 28:704-712.
5. REICHEL H, DEIBERT B, SCHMIDT-GAYK H, RITZ E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant. (1991) 6:162-169.
6. PITTS TO, PIRAINO BH, MITRO R et al.: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. (1988) 67:876-881.
7. SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. (1999) 56:S14-S19.
8. SLATOPOLSKY D, BROWN A, DUSSO A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am. J. Kidney Dis. (2001) 37(Suppl. 2): S54-S57.
9. SLATOPOLSKY E, FINCH J, DENDA M et al.: Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J. Clin. Invest. (1996) 97:2534-40.
10. ALMADEN Y, CANALEJO A, HERNANDEZ A et al.: Direct effect of phosphorus on PTH secretion from whole rat parathyroid gland in vitro. J. Bone Miner. Res. (1996) 11:970-976.
11. DENDA M, FINCH J, SLATOPOLSKY E: Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am. J. Kidney Dis. (1996) 28:596-602.
12. SILVER J, NAVEH-MANY T, MAYER H et al.: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. (1986) 78:1296-1301.
13. RUSSELL J, LETTIERI D, SHERWOOD LM: Suppression by 1,25 (OH) D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology (1986) 119:2864-2866.
14. GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. (1997) 51:328-336.
15. FUKADA N, TANAKA H, TOMINAGA Y, FUKAGAWA M, KUROKAWA K, SEINO Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremia patients. J. Clin. Invest. (1993) 92:1436-1443.
16. COZZOLINO M, BRANCACCIO D, GALLIENI M, SLATOPOLSKY E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. (2005) 68:429-436.
17. KETTLER M, GROSS M, RITZ E: Calcification and cardiovascular problems in renal failure. Kidney Int. (2005) 67(Suppl. 94):S120-S127.
18. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
19. GANESH SK, STACK AG, LEVIN NW et al.: Association of elevated serum PO(4), CaxPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
20. BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
21. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-S201.
22. MEE AP, DAVENPORT LK, HOYLAND JA, DAVIES M, MAWER EB: Novel and sensitive detection systems for the vitamin D receptor - in situ reverse transcriptase-polymerase chain reaction and immunogold cytochemistry. J. Mol. Endocrinol. (1996) 16:183-196.
23. DUSSO AS, BROWN AJ: Mechanisms of vitamin D action and its regulation. Am. J. Kidney Dis. (1998) 32(Suppl.):13-24.
24. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcifications in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2003) 342:1478-1483.
25. QUNIBI WY, NOLAN CA, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int. Suppl. (2002) 82:73-80.
26. MALLIK NP, BERLYNE GM: Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet (1968) 2:1316-1320.
27. GOLDSMITH D, RITZ E, COVIC A: Vascular calcification: a stiff challenge for the nephrologist; does preventing bone disease cause arterial disease? Kidney Int. (2004) 66:1315-1333.
28. COBURN J, MAUNG H, ELANGOVAN L et al.: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. (2004) 43(5):877-890.
29. SLATOPOLSKY E, FINCH J, RITTER C et al.: A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. (1995) 26:852-860.
30. HOLLIDAY LS, GLUCK SL, SLATOPOLSKY E, BROWN AJ: 1,25-Dihydroxy-19-nor-vitamin D (2), a vitamin D analog with reduced bone resorbing activity in vitro. J. Am. Soc. Nephrol. (2000) 11:1857-1864.
31. FINCH JL, BROWN AJ, SLATOPOLSKY E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin-D2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. (1999) 10:980-985.
32. MARTIN KJ: Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double blind, multicenter, radomized study. Am. J. Kidney Dis. (2001) 38(Suppl.):S57-S63.
33. SPRAGUE SM: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am. J. Kidney Dis. (2001) 38(Suppl.):S51-S56.
34. LLACH F, YUDD M: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathydoisim. Am. J. Kidney Dis. (2001) 38(Suppl.):S45-S50.
35. TENG M, WOLF M, LOWRIE E, OFSTHUN N, LAZARUS M, THADHANI R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Engl. J. Med. (2003) 349:446-456.
36. COYNE DW, ACHARYA M, QIU P et al.: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am. J. Kidney Dis. (2006) 47(2):263-276.
37. QUARLES LD, YOHAY DA, CARROLL BA et al.: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. (1994) 45:1710-1721.
38. LEVINE BS, SONG M: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J. Am. Soc. Nephrol. (1996) 7:488-496.
39. QUARLES LD, INDRIDASON OS: Calcitriol administration in end-stage renal disease: intravenous or oral? Pediatr. Nephrol. (1996) 10:331-336.
40. HAMDY NA, KANIS JA, BENETON MN et al.: Effect of alfacalcidol on natural course of renal bone disease in mild and moderate renal failure. Br. Med. J. (1995) 310(6976):358-363.